FDA OKs First Targeted Therapy for Rare Blood Clotting Disorder FDA OKs First Targeted Therapy for Rare Blood Clotting Disorder

Caplacizumab (Cablivi) injection is indicated in combination with plasma exchange and immunosuppressive therapy for adults with acquired thrombotic thrombocytopenic purpura (aTTP).FDA Approvals
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news